Method and Apparatus for Diagnosing and Assessing Centralized Pain by Hargrove, Jeffrey
Kettering University 
Digital Commons @ Kettering University 
Mechanical Engineering Patents Mechanical Engineering 
7-23-2015 
Method and Apparatus for Diagnosing and Assessing Centralized 
Pain 
Jeffrey Hargrove 
Kettering University, jhargrov@kettering.edu 
Follow this and additional works at: https://digitalcommons.kettering.edu/mech_eng_patents 
 Part of the Bioelectrical and Neuroengineering Commons 
Recommended Citation 
Hargrove, Jeffrey, "Method and Apparatus for Diagnosing and Assessing Centralized Pain" (2015). 
Mechanical Engineering Patents. 10. 
https://digitalcommons.kettering.edu/mech_eng_patents/10 
This Patent is brought to you for free and open access by the Mechanical Engineering at Digital Commons @ 
Kettering University. It has been accepted for inclusion in Mechanical Engineering Patents by an authorized 
administrator of Digital Commons @ Kettering University. For more information, please contact 
digitalcommons@kettering.edu. 
US 2015020 1879A1 
(19) United States 
(12) Patent Application Publication (10) Pub. No.: US 2015/0201879 A1 
Hargrove (43) Pub. Date: Jul. 23, 2015 
(54) METHOD AND APPARATUS FOR (52) U.S. Cl. 
DAGNOSING AND ASSESSING CPC ............... A61B 5/4827 (2013.01); A6IB5/055 
CENTRALIZED PAN (2013.01); A61B5/0484 (2013.01); A61B 
5/0053 (2013.01); A61B5/0057 (2013.01); 
(71) Applicant: Cerephex Corporation, Los Altos, CA A61B 5/7257 (2013.01); A61B5/7235 
(US) (2013.01); A61B5/483 (2013.01) 
(72) Inventor: Jeffrey B. Hargrove, Bancroft, MI (US) 
(57) ABSTRACT 
(21) Appl. No.: 14/417,142 
(22) PCT Filed: Jul. 24, 2013 Methods for central pain diagnosis and assessment, symptom 
severity prediction, and therapeutic intervention effect deter 
(86). PCT No.: PCT/US2013/051867 mination. The diagnosis and assessment method includes a 
S371 (c)(1) statistical comparison between a subjects quantitative brain 
(2) Date: s Jan. 24, 2015 function assessment and either a database of quantitative 
assessments of brain functions of healthy individuals, or a 
Related U.S. Application Data database of quantitative assessments of brain functions of 
individuals known to have been Suffering from chronic pain 
(60) Provisional application No. 61/675,190, filed on Jul. as a result of the abnormal brain function condition. Diagno 
24, 2012. sis and assessment may be accomplished using a neuroimag 
Publication Classification ing device to sense and generate images representing central 
nervous system function, using a sensory stimulation device 
(51) Int. Cl. to stimulate brain activities associated with central sensitiv 
A6 IB5/00 (2006.01) ity, and using a computing device to command the sensory 
A6 IB5/0484 (2006.01) stimulation device and neuroimaging device to test for the 




Neuroint asiris : 
. : s 




- - - - - - - 
ig -i. 8:ais S&six-rise 
------ -a, -, -----...-- s SE &s & ifs 
-x ry------ 
or to Sensory s 








Patent Application Publication Jul. 23, 2015 Sheet 1 of 9 US 2015/02O1879 A1 
YY w Y w s 












US 2015/02O1879 A1 
32 
rxxxxxxaakas-r----- 














Patent Application Publication 
Silp 
& 38& r. ii to sealthy S. 
sy&s: 3; issorials; 





Patent Application Publication 
... ...S. * RSS 










Patent Application Publication 
. . 
stiniaxis is &ersists:s: 
: 8 ps&sers sis's stics 
XŠsiiii:g 
is-cis 
its res: - 
in S C E: 
wa. 










Patent Application Publication Jul. 23, 2015 Sheet 6 of 9 US 2015/0201879 A1 
Sta: 
F 
{}iagnose a 'd 8ssess Centra path using a brai response test Esgrising a rauroimaging 
t&st 8:cts as an EES test knciliated for a petic d of iris isfy is as cat:3th of &isy & the or 
r^{re: sensory skita 333ions that fight st:s& the of agre if air rasparses 
58 
60 laalaalaall--------- TT-M 
Ps for Y }rse of tisse additional sessoinagig tests for a Fei ad of tire is sting the 
appisic's f{}rts of the re; (3xios or nor-gxiss, pair its ring irritor-pair triciting 
serisay stirnsatists such as a terties' point test, aspiisi win a fascissista 8:sissire &rsary 
paft of the 38ty, apication of either fcitris of reciyanicat stiristiatio; to 3ry patt is the 
bedy, applications of as: 28C3rical stir-ult:3, agitation: Cfa heast-producing stimuius, is wiv3 
or in witi ) is toductier of 8 chi:ricatasant, inexarkal krishing, ex: street is hysical 
f:3vetests ride by the subject, if ferrils of Ysartial strocassig scs as cositive exerciss: 
62 asy of which say the sorceived to case sects rice if it respons&s 
N Repeat are or sacre senses stiris: atlais &sdore of '38te issuriyaging tests owe & 
64 p&riod of tire is ski:h a way as ic prix lace is recor ruitish trair, esponses 
N Periorry cre of n:o reads:tional sieureiraging tests of a peries aftinia after she 
siegication of the orts & fiere se?sSofy stimatic; ins 
-T - - - - - - - Y - 
(fe8te & Ebrain isspose test raci that Eristies a stified as sisters sri sististics of 
iseufossilagirig tests, ans: those parameters associated with tihe one of rife sensory 
Stinsulations is settsiing $38 rainsters sit as locatios of $8:hanica a? assure, assasst ai 
mechassical pressure, parameters of other fortas of recitanics stimusi, gafarieters of 
for as of alectrical sittivisii, (3rarieties ifiers if heat stirnt sti, p8; 8 meters of ai. 
S. 
itrogstec chanics: ags it, afaete's of bisis strikes, t: pararieters ( & &isia 
&xercise; arid stiti cuisitifs: 8 F3 state's ircis?istics& accursisig as of shear the tins of 
agpitatsor if the cris: ix nsore serispy stirrigations 
68 viruvvuvvarreraserae 
8sses giated with zer if a sais, atter with or 
k witholi: sagarasiting shysica assessmeist, by assessing a brain esponse test recKirei Šor 
charges is r&h 'essorse is seisgy stinuations overtists to discover are errore traf 
activities, such as those associates with eefstra sei:sitivity if Baxx final x is if network 
70 connectivity, folkswirs, the apstigatio of the she or it of a sersary si tif: 
3rd assess Certist pais 3sed of a;3 yzing fidi R5 fro: (38 of safe faith 
response tests to dists: irise ase &r Yefe b:sin activities, sketch as those assiciated with 
cents as sensitivity or air armai is r&ir setwork to sitectivity, is st:sport & disgiosis of 
{{2iralized Jai, &th& with of with 33i 3 SE 8tistica is parison for Sikes ess if deviatics is 
etweei: 8 Fly (Reg. E1are of the st:tiet's trairies::)isse test ressures essed data 83588 it 
iské: train response test flies suites 3f either taaitiy for Yai individuals, ir:dividuals stiffering 










Patent Application Publication Jul. 23, 2015 Sheet 7 of 9 US 2015/0201879 A1 
Start ) 
Execute a brain response test on a subject 
72 
74 
Obtain measures of brain activities associated with central pain in the subject by 
analyzing findings from the brain response testing 
76 
Correlate measures of brain activities to measures of symptom severity 
Subsequently predict symptom severity in individuals having central pain by using 




Patent Application Publication Jul. 23, 2015 Sheet 8 of 9 US 2015/0201879 A1 
72 
ravaararu-ri arror-rry YYYYYrarraraYYYYYYY 
Executie 3 if air respoise test of 8 skinje: 
74 
titain in seasuses of ; as activities associetecs with Cest rst air in the subject by 
analyzing fiftdings fren, the bis is respoise testing 
-T 
-------------YYYYYYYee-eeee 
Correiate 3 seasses of this is sistilises to reasires of its &$$ect of 3 therapeutic 
iate:"wentici for aiiewisting syrptons of Castal gait 
Sutsesserty gredict the effect of a tiss raisetic intervertists in alleviating symptons of 
{eistra sai' is Eniwidt:als saying cast raisi by tising its thesistical (c)3 relatiof sixes 
of the effect of a therapatic intervertier if atteviating syptons of cent at air as a 








Patent Application Publication Jul. 23, 2015 Sheet 9 of 9 US 2015/02O1879 A1 
y s . 












wn w y wr x -- a--a - - - - 
- - - - 
  
US 2015/020 1879 A1 
METHOD AND APPARATUS FOR 
DAGNOSING AND ASSESSING 
CENTRALIZED PAN 
TECHNICAL FIELD 
0001. The present invention relates generally to the field of 
diagnosing central pain disorders. More specifically, the 
present invention relates to methods and apparatuses for diag 
nosing abnormal pain processing function or mechanisms in 
the brain that result in central pain disorders in human Sub 
jects. 
BACKGROUND 
0002 Nociceptive pain is known to arise from stimulation 
of peripheral nerve endings. In response to such stimulation, 
a peripheral nerve ending generates a peripheral nociceptive 
signal that is then transmitted through the spinal cord to the 
brain, where it is processed through numerous pain-process 
ing networks. Descending pathways from the brain to the 
spinal cord Subsequently modulate pain signals, thereby 
increasing or decreasing pain perception. 
0003. However, it is also known that enhanced activation 
of central pain-processing pathways and networks, through 
mechanisms such as neuroplastic changes in central neuronal 
activity and network connectivity, can lead to spontaneous 
pain in the absence of peripheral nociceptive input. When this 
occurs, pain is said to have “centralized, which results in 
lower pain thresholds, secondary hyperalgesia in uninjured 
areas, and Sustained pain potentiation. Brain-related central 
pain (also known as “centralized pain') is thought to play a 
prominent role in chronic pain conditions. 
0004 Central pain is generally thought of as an outcome 
of central sensitivity (CS), which is also known as central 
sensitization, central augmentation, and central hypersensi 
tivity among other terms. CS mechanisms in the brain have 
been implicated in the pathology of allodynia, which is the 
term used to describe a condition where pain is caused by a 
stimulus that does not normally provoke pain. CS mecha 
nisms in the brain have also been implicated in hyperalgesia, 
which is the term used to describe a condition in which pain 
perceived from a stimulus is greater than what would nor 
mally be expected from that stimulus. Put simply, in central 
sensitivity the brain magnifies painful stimuli and eventually 
magnifies even associated non-painful stimuli. As pointed out 
in Latremoliere and Woolfe (1), because CS results from 
changes in the properties of neurons in the central nervous 
system, the pain is no longer coupled, as acute nociceptive 
pain is, to the presence, intensity, or duration of noxious 
peripheral stimuliarising from neuropathic and/or inflamma 
tory sources. Further, in chronic pain conditions the increased 
excitability caused by CS far outlasts the initiating noxious 
stimulus, that is, the nociceptive input that causes the pain to 
occur in the first place. 
0005 Before CS was discovered, typically only two mod 
els of pain were contemplated. The first is the aforementioned 
nociceptive pain model, by which specific pain pathways are 
activated by peripheral pain stimuli, and the amplitude and 
duration of the pain experienced is determined entirely by the 
intensity and timing of the peripheral pain inputs. The second 
model contemplates gate controls in the central nervous sys 
tem that open and close, thus enabling or preventing pain. 
Medical science now recognizes CS as a third and unique 
model that contemplates neuroplastic changes in the func 
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tional properties and network connectivity of the central ner 
Vous system. For example, the level of resting brain activity 
within multiple networks (e.g. functional network connectiv 
ity and effective network connectivity) is now known to be 
associated with spontaneous pain in patients having central 
pain (2, 3). CS leads to reductions in pain threshold, increases 
in the magnitude and duration of responses to noxious input, 
and permits normally innocuous inputs to generate pain sen 
sations. In addition, CS is also believed to be relevant in 
Somatic symptoms associated with painful conditions, 
including but not limited to fatigue and sleep disorders. 
0006. The brain's role in CS is being increasingly revealed 
and understood in neuroscience, due in large part to the 
advent of functional brain imaging technologies. For 
example, Lee et al. (4) used functional magnetic resonance 
imaging (fMRI) to examine the extent to which brain activity 
contributes to the maintenance of CS in humans. When the 
intensity of pain during CS was matched to the intensity of 
pain during normal states, activity within the brainstem, 
including the mesencephalic pontine reticular formation and 
the anterior thalami, remained at an increased level during 
CS. Regarding brain areas related to the consequence of 
increased pain perception during CS, cortical activity, mainly 
in the primary Somatosensory area, has been significantly 
correlated with the intensity of pain attributable to both the 
force of noxious stimulation used, and the state in which 
noxious stimulation was applied. 
0007 Borsook et al. (5) reviewed the literature on brain 
activity using neuroimaging technologies. Their review 
details evidence of alterations in multiple sub-cortical and 
cortical processing mechanisms. Those alterations include 
sensory, emotional/affective, cognitive, and modulatory sys 
tems that are present in chronic pain. The authors note these 
findings provide evidence that increases understanding of the 
importance of the role of numerous brain regions in the cen 
tralization of pain and the contributions of those regions to the 
altered brain states associated with chronic pain conditions. 
Similarly, Schweinhardt and Bushnell (6) review neuroimag 
ing evidence of the active and enhanced modulatory role that 
the brain plays in pain processing in chronic pain patients. 
Schwienhardt and Bushnell also cite findings that brain acti 
Vations in chronic pain involve brain circuitry not normally 
activated by acute nociceptive pain. 
0008 Because of this emerging understanding, the role of 
CS is increasingly being shown to be pathological in seem 
ingly unrelated chronic pain conditions and syndromes 
including fibromyalgia, complex regional pain syndrome, 
phantom pain, and migraine headaches. Yunus (7) identifies 
no less than 14 common syndromes that lack structural 
pathology yet have CS as a common mechanism. These con 
ditions further include chronic fatigue syndrome, irritable 
bowel syndrome, tension-type headaches, temporomandibu 
lar disorder, myofascial pain syndrome, regional soft-tissue 
pain syndrome, restless leg syndrome, periodic limb move 
ments in sleep, multiple chemical sensitivity, primary dys 
menorrhea, female urethral syndrome, interstitial cystitis, 
and post-traumatic stress disorder. Yunus also notes that CS 
may play a significant role in the pain associated with depres 
sion and in Gulf War Syndrome. 
0009 Giesecke et al. (8) used fMRI to demonstrate aug 
mented central pain processing in patients with idiopathic 
chronic low back pain and fibromyalgia. Indeed, when equal 
levels of mechanical pressure intended to elicit a painful 
response were applied to patients and to normal controls, 
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patients with chronic low back pain and fibromyalgia expe 
rienced significantly more pain and showed more extensive, 
common patterns of neuronal activation in pain-related cor 
tical areas of the brain than did the controls. Thus, CS may 
play an important role in persons with chronic low back pain 
that persists without identifiable physical pathology. 
0010. The role of CS in persistent inflammatory condi 
tions is also gaining recognition. In Gwilym et al. (9), fMRI 
illustrated significantly greater brainactivation in osteoarthri 
tis (OA) patients in response to stimulation of their referred 
pain areas (i.e. areas where pain persists but do not exhibitOA 
or related inflammation) compared with healthy controls, and 
the magnitude of this activation positively correlated with the 
extent of neuropathic-like elements to the patient’s pain. The 
role of CS in osteoarthritis has been the subject of several 
other investigations (10, 11, 12). As detailed in Imamura et al. 
(13), the refractory, disabling pain associated with knee OA is 
usually treated with total knee replacement. However, a com 
parison of OA patients with healthy normal controls showed 
patients with knee OA had significantly lower pressure pain 
thresholds (PPT) over widespread evaluated structures 
beyond the knee. The lower PPT values were correlated with 
higher pain intensity, higher disability Scores, and with poorer 
quality of life. This suggests that pain in these patients might 
be more associated with CS than with peripheral inflamma 
tion and injury. As the authors point out, the implications of 
the role of CS, and its potential for modulation, may provide 
exciting and innovative cost effective therapeutic tools to 
control pain, reduce disability, and improve quality of life in 
knee OA patients. 
0011. The diagnosis of pain generally fails to differentiate 
central pain processes in the brain from peripheral pain aris 
ing from an ongoing noxious stimulus. Diagnosing central 
pain is usually only made empirically after multiple failed 
therapeutic attempts reveal its likely presence. This practice 
results in unmet expectations for both patients and physi 
cians, and contributes to high healthcare costs in the chronic 
pain clinical population. The ability to develop quantitative 
real-time diagnostic and assessment methods for central pain, 
especially methods and apparatuses making Such diagnosis 
and assessment practical at the point-of-care, would be a 
significant clinical advancement. Such would improve phy 
sicians’ ability to appropriately and immediately match treat 
ments to the relevant pain mechanism, thus saving time and 
reducing healthcare costs. 
0012. Of relevance to the present invention, it is known 
that neurophysiologic information may be obtained by tech 
niques such as electroencephalography (EEG) and fMRI. It is 
also known that fMRI can be used to measure neurotransmit 
ter and neuroreceptor activity. It is also known that the analy 
sis of numerous brain imaging and functional measures, 
including EEG measures (13), have been shown to produce 
measures related to brain networks and network connectivity 
that correlate to findings produced by fMRI imaging (14). 
Thus, the presence of brain activity associated with CS, and 
hence central pain, can be determined using EEG measures 
and analysis. 
0013 The following documents are incorporated by ref 
erence in their entirety: 
0014 “Central sensitization: a generator of pain hypersen 
sitivity by central neural plasticity'. Latremoliere A. Woolf 
CJ. J. Pain. 2009 September; 10(9):895-926. 
00.15 “Intrinsic brain connectivity in fibromyalgia is asso 
ciated with chronic pain intensity, Napadow V. LaCount 
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L. Park K, As-Sanie S, Clauw DJ, Harris R. E. Arthritis 
Rheum. 2010 August: 62(8):2545-55. 
0016 “Disrupted functional connectivity of the pain net 
work in fibromyalgia”, Cifre I, Sitges C, Fraiman D, 
Muñoz MA, Balenzuela P. González-Roldán A. Martinez 
Jauand M. Birbaumer N. Chialvo DR. Montoya P. Psycho 
som Med. 2012 January: 74(1):55-62. 
0017 “Identifying brain activity specifically related to the 
maintenance and perceptual consequence of central sensi 
tization in humans', Lee MC, Zambreanu L, Menon DK. 
Tracey I. J Neurosci. 2008 Nov. 5; 28(45): 11642-9. 
0018. A key role of the basal ganglia in pain and analge 
sia—insights gained through human functional imaging. 
Borsook D, Upadhyay J, Chudler E. H. Becerra L. Mol 
Pain. 2010 May 13: 6:27. 
0019. “Pain imaging in health and disease—how far have 
we come?'. Schweinhardt P. Bushnell M. C. J. Clin Invest. 
2010 Nov. 1; 120(11):3788-97. 
0020 “Fibromyalgia and overlapping disorders: the uni 
fying concept of central sensitivity syndromes, Yunus M 
B. Semin Arthritis Rheum. 2007 June; 36(6):339-56. 
0021. “Evidence of augmented central pain processing in 
idiopathic chronic low back pain'. Giesecke T. Gracely R 
H, Grant MA, Nachemson A, Petzke F. Williams D A, 
Clauw DJ. Arthritis Rheum. 2004 February:50(2): 613–23. 
0022 “Psychophysical and functional imaging evidence 
Supporting the presence of central sensitization in a cohort 
of osteoarthritis patients', Gwilym S. E. Keltner J. R. 
Warnaby C. E. Carr AJ, Chizh B, Chessell I, Tracey I. 
Arthritis Rheum. 2009 Sep. 15: 61 (9): 1226-34. 
0023 "Lessons from fibromyalgia: abnormal pain sensi 
tivity in knee osteoarthritis, Bradley L. A. Kersh B C, 
DeBerry J.J. Deutsch G, Alarcón GA, McLain DA. Novar 
tis Found Symp. 2004; 260:258-70. 
0024) “Sensitization in patients with painful knee osteoar 
thritis', Arendt-Nielsen L. Nie H, Laursen MB, Laursen B 
S. Madeleine P. Simonsen O H, Graven-Nielsen T. Pain. 
2010 June; 149(3):573-81. 
0025 “Pain mechanisms in osteoarthritis: understanding 
the role of central pain and current approaches to its treat 
ment, Mease PJ. Hanna S. Frakes E. P. Altman R D. J 
Rheumatol. 2011 August;38(3):1546-51. 
0026 "Impact of nervous system hyperalgesia on pain, 
disability, and quality of life in patients with knee osteoar 
thritis: a controlled analysis”. Imamura M, Imamura S. T. 
Kaziyama H. H. Targino RA, Hsing W T de Souza L. P. 
Cutait M M, Fregni F, Camanho G. L. Arthritis Rheum. 
2008 Oct. 15:59(10): 1424-31. 
0027 “Functional connectivity: the principal-component 
analysis of large (PET) data sets”. Friston K.J. Frith CD, 
Liddle P F, Frackowiak R. S. J. Cereb Blood Flow Metab 
1993; 13:5-14. 
0028 “Electrophysiological signatures of resting state 
networks in the human brain'. Mantini D, Perrucci MG, 
Del Gratta C, Romani GL, Corbetta M. Proc Natl Acad Sci 
USA. 2007 Aug. 7: 104(32): 13170-5. 
(0029 U.S. patent application Ser. No. 12/865,286 filed 
Jul. 29, 2010 as a 371 of PCT/US09/32639, published on 
Dec. 23, 2010 as Pub. No. US2010/324441 A1, and 
assigned to the assignee of the present application; 
0030 U.S. Provisional Patent Application Ser. No. 
61/024,641, filed Jan. 30, 2008 and assigned to the 
assignee of the present application; 
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0031 U.S. Provisional patent application Ser. No. 12/865, 
286, filed Jul. 29, 2010 and assigned to the assignee of the 
present application; 
0032 U.S. Provisional Patent Application Ser. No. 
61/644,049, filed May 8, 2012 and assigned to the assignee 
of the present application. 
SUMMARY 
0033. A method is provided for diagnosing and assessing 
central pain. The method may include the steps of assessing a 
subjects brain function, determining the probability that a 
Subject is suffering from chronic pain as a result of an abnor 
mal brain function condition by obtaining a quantitative 
assessment of the Subjects brain function, and 
0034) making a statistical comparison between the sub 
ject’s quantitative brain function assessment and either a 
database of quantitative assessments of the brain functions of 
normal, healthy individuals, or a database of quantitative 
assessments of the brain functions of individuals known to 
have been Suffering from chronic pain as a result of the 
abnormal brain function condition. 
0035. The method may alternatively include assessing a 
subjects brain function using a brain response test (BRT) 
comprising the steps of performing one or more baseline 
neuroimaging tests, causing one or more brain responses by 
applying one or more sensory stimulations, and performing 
one or more neuroimaging tests after the step of causing one 
or more brain responses. The method may also include the 
steps of obtaining a quantitative assessment of the subjects 
brain function and making a statistical comparison between 
the Subject’s quantitative brain function assessment and one 
or more databases of quantitative assessments of the brain 
functions. 
0036. A method is provided for predicting symptom sever 
ity in individuals having central pain. The method may 
include the steps of executing a brain response test on a 
Subject, obtaining measures of brain activities associated with 
central pain in the Subject by analyzing findings from the 
brain response testing, correlating these measures of brain 
activities to measures of symptom severity, creating a math 
ematical correlation model that provides symptom severity as 
a function of the measures of brain activities, and Subse 
quently using the mathematical correlation model to predict 
symptom severity in individuals having central pain when 
measures of brain activities are known. 
0037. A method is provided for determining the effect of a 
therapeutic intervention in alleviating symptoms of central 
pain. The method may include the steps of executing a brain 
response test on a Subject, obtaining measures of brain activi 
ties associated with central pain in the Subject by analyzing 
findings from the brain response testing, correlating these 
measures of brain activities to measures of the effect of a 
therapeutic intervention, creating a mathematical correlation 
model that provides the effect of therapeutic intervention as a 
function of the measures of brain activities, and Subsequently 
using the mathematical correlation model to predict the effect 
of therapeutic intervention in alleviating symptoms of central 
pain when measures of brain activities are known. 
0.038 An apparatus for diagnosing and assessing central 
pain is provided, which may comprise a neuroimaging device 
that is configured to sense and generate images representing 
central nervous system function, a sensory stimulation device 
that is configured to stimulate brain activities associated with 
central sensitivity, and a computing device that is coupled to 
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the neuroimaging device and the sensory stimulation device 
and configured to command the sensory stimulation device 
and neuroimaging device. The apparatus may be configured 
to perform a brain response test for the presence of central 
pa1n. 
BRIEF DESCRIPTION OF THE DRAWINGS 
0039. These and other features and advantages of the 
invention will become apparent to those skilled in the art in 
connection with the following detailed description and draw 
ings, in which: 
0040 FIG. 1 is a flow chart depicting a method for diag 
nosing fibromyalgia; 
0041 FIG. 2 is a flow diagram of a method of diagnosing 
and assessing central pain; 
0042 FIG. 3 is a flow diagram of a method of predicting 
symptom severity in individuals having central pain; 
0043 FIG. 4 is a flow diagram of a method of determining 
the effect of a therapeutic intervention in alleviating Symp 
toms of central pain; and 
0044 FIG. 5 is a schematic diagram showing an embodi 
ment of an apparatus for diagnosing and assessing central 
pain. 
DETAILED DESCRIPTION 
0045. In the following description of the disclosed appa 
ratus and methods, the term "central pain', which is also 
known as "centralized pain', is intended to mean any form of 
pain, whether chronic or acute, that is enhanced in its char 
acteristics; such as magnitude, duration and scope; due to 
abnormalbrain activity associated with pain processing. Such 
brain activity may include, but is not limited to, central sen 
sitivity and network connectivity. 
0046. The term “central sensitivity” is intended to mean 
any central nervous system condition pathologically related 
to hyperalgesia, allodynia, reductions in pain threshold, 
increases in the magnitude and duration of responses to nox 
ious input, results in normally innocuous inputs to generate 
pain sensations, or results in non-painful symptoms associ 
ated with increases in central nervous system responsiveness. 
Central sensitivity is also known by alternate terms that 
include but are not limited to “central sensitization”, “central 
pain', 'central augmentation.” and “central hypersensitiv 
ity”. 
0047 Central sensitivity is not a manifestation or cause of 
an individual symptom or condition. Instead, central sensi 
tivity results in a worsening of the effect or magnitude of one 
or more symptoms because of a central nervous system con 
dition that is independent of the cause of the one or more 
symptoms per se. Thus, any method of treatment of central 
sensitivity is fundamentally different from treatment of a 
specific symptom. For example, treatment of pain augmenta 
tion by central sensitivity is inherently different than treat 
ment of pain under traditional nociceptive models of pain. 
0048. The terms “network connections” and “network 
connectivity” are intended to mean various forms of relation 
ships between brain regions involved in processing of infor 
mation Such as pain. For example, “functional connectivity” 
refers to a statistical correlation between the activities of 
different brain regions. “Effective connectivity” denotes not 
simply a statistical but a causal influence between two brain 
regions. 
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0049. The term “alleviate' or “alleviating is intended to 
mean the act of reducing, making less severe, mitigating, 
treating, or eliminating a condition and/or its symptoms for 
any period of time. 
0050 Except where the context requires otherwise, the 
term “comprise' and variations of the term, such as “com 
prising”, “comprises” and “comprised' are not intended to be 
exclusive. Where, for example, a form of the word “com 
prise' is used to refer to one or more additives, components, 
integers or steps; its use is not intended to exclude other 
additives, components, integers or steps. 
0051. Where the terms “integral” or “integrated” are used 
to describe a relationship between two or more elements, the 
terms are intended to indicate that such elements are joined 
together in a manner that does not allow separation of ele 
ments from one another without diminishing or destroying a 
function of one or more of the elements. 
0052. The term “stimulation signal' is intended to mean 
any energy signal used in the process of stimulating a tissue 
Such as a brain by transmitting an energy signal generated by 
a device Such as an electrical stimulator, or a magnetic stimu 
lator Such as a transcranial magnetic stimulator. Other terms 
used to refer to Such a signal may include but are not limited 
to “cortical stimulation”, “neuromodulation' and “neuro 
stimulation'. 
0053. The term “neuroimaging test” is intended to mean 
any medical test that provides visual indication, measures, or 
other data that can be used to make an assessment about 
central nervous system function, including brain function. 
Types of tests that the term “neuroimaging test may be used 
to refer to include, but are not limited to, magnetic resonance 
imaging, computer aided tomography, positron emission 
tomography, or single photon emission computed tomogra 
phy, and may also include brain electrical function tests Such 
as electroencephalography or magnetoencephalography. 
0054) The term “brain activities” is intended to refer to any 
brain activities that are known in the art to be associated with 
central sensitivity. Such brain activities are intended to 
include, but are not limited to, abnormal condition, abnormal 
function, abnormal response, abnormal regions of activation, 
abnormal network connectivity, abnormal release of neuro 
chemicals, abnormal uptake of neurochemicals, abnormal 
electrical activity, or abnormal metabolism. 
0055. The term “brain function' is intended to mean any 
action or process of a brain that is within the brain's normal 
state of operation. 
0056. The term “spectral segments” is intended to mean 
frequency components of an electrical signal that includes 
individual frequency components, and in the case of an EEG 
signal, that includes groupings of frequency components 
commonly known as “frequency bands'. Such bands includ 
ing, but not limited to the “delta” band (nominally 1-3.5 
hertz), the “theta' band (nominally 4-7.5 hertz), the “alpha 
band (nominally 8-12 hertz) and the “beta’ band (nominally 
12.5-25 hertz). 
0057 The term “resting EEG” is intended to mean elec 
troencephalogram signals that are collected with the Subjects 
eyes either open or closed and during periods of no significant 
physical activity, mental activity, or any otherform of engage 
ment that may cause the brain to be stimulated significantly or 
engaged in elevated brain function. 
0058. A method is provided for diagnosing and assessing 
a brain-related chronic pain disorder. The method includes 
assessing a human Subject's brain function and then deter 
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mining the probability that the subject is suffering from 
chronic pain related to an abnormal brain function condition 
by obtaining a quantitative assessment of the Subject's brain 
function and making a statistical comparison between the 
Subject’s quantitative brain function assessment and a data 
base of quantitative assessments of the brain functions of 
individuals known to have been Suffering from chronic pain 
as a result of the abnormal brain function condition. The 
assessment of a Subject's brain function may include obtain 
ing an electroencephalogram (EEG) of the Subjects electrical 
brain activity, and the determination of the probability that the 
Subject is suffering from chronic pain as a result of an abnor 
mal brain function condition may include determining the 
probability that the subject is suffering from a chronic pain 
condition Such as fibromyalgia by obtaining a quantitative 
assessment of the Subject's EEG (dEEG) and making a sta 
tistical comparison between the subject’s qEEG and a data 
base of qBEGs of individuals known to have been suffering 
from fibromyalgia. 
0059 A physical assessment may first be performed of a 
human Subject presenting with a complaint of symptoms 
characteristic of a chronic pain condition Such as fibromyal 
gia. The physical assessment may include, among other 
things, a determination of chronic widespread pain, sleep 
difficulty, fatigue, morning stiffness of the muscles and joints, 
cognitive difficulty and other symptoms associated with the 
condition. Where, for example, fibromyalgia is suspected, the 
physical assessment may also include tests performed to 
exclude various non-fibromyalgia conditions as the cause of 
the symptoms. Such further testing may include palpation of 
18 tender points in the manner prescribed by the American 
College of Rheumatology (ACR), with Such palpation being 
performed to determine whether the subject has an abnormal 
sensitivity to pain. Where, for example, idiopathic chronic 
low back pain ICLBP) is suspected, the physical assessment 
may include tests performed to exclude various non-ICLBP 
conditions as the cause of the symptoms. Such further testing 
may include palpation of tender points other than the 18 
tender points prescribed by the ACR and/or may include 
physical tests other than tender point palpation. 
0060. In the absence of a definitive diagnosis, an EEG test 
may be performed in addition to the physical assessment. 
Specifically, the subject may be made comfortable by, for 
example, being seated or reclined. Preparation of the scalp in 
accordance with commonly followed procedures for per 
forming a clinical EEG may be done by a person of sufficient 
competence. EEG electrodes may then be adapted to be worn 
on the scalp, preferably in Scalp locations identified as the 
“International 10-20” standard sites, using common methods 
of affixing the electrodes such that they rest on or otherwise 
contact tissues. 
0061 While any number of electrodes may be used, a 
preferred number is either 19 or 24, in accordance with the 
number of electrode sites used to construct various indepen 
dent databases utilized to represent the EEG of a healthy 
normal population. 
0062 Records of the subject's EEG from each electrode 
site may then acquired under the conditions of both their eyes 
being closed and their eyes being open, with each condition 
producing a separate data record. In other words, an “eyes 
open EEG record may be obtained, which includes EEG data 
obtained from each electrode site while the subject’s eyes are 
open and an “eyes closed EEG record may be obtained, 
which includes EEG data obtained from each electrode site 
US 2015/020 1879 A1 
while the subject’s eyes are closed. Preferably, a minimum of 
five minutes of EEG data may be obtained from each elec 
trode site for each "eyes open EEG record and a minimum of 
five minutes of EEG data may be obtained from each elec 
trode site for each "eyes closed EEG record to assure that 
enough EEG data is recorded to produce statistically signifi 
cant samples from each electrode site, both with the subjects 
eyes open and with the subject’s eyes closed. This is further 
described below. 
0063 Preferably, an additional test may be performed in 
which at least one additional EEG record is made that 
includes EEG data obtained at each electrode site while pain 
is elicited in the Subject. In diagnosing or assessing conditions 
Such as fibromyalgia, a number of tender points on the Sub 
jects body may be palpated. In this test, henceforth referred 
to as a “tender point palpation (TPP) test”, a number of tender 
points on the Subject’s body, preferably ranging between one 
and 18 when diagnosing or assessing fibromyalgia, are iden 
tified and serially palpated, preferably with an algometer. 
Preferably, four tender points may be chosen, and, preferably, 
those four points include tender points adjacent the right and 
left lateral epicondyle of the arms, and tender points adjacent 
the right and left costochondral junctions of the second rib. 
While the subject’s eyes are preferably closed during this test, 
it should not be confused with the “eyes closed’ test described 
above. 
0064. The TPP test may be executed by acquiring an EEG 
record (“TPP” EEG record) including EEG data obtained 
from the electrode sites for a first tender point by first com 
mencing the acquisition of EEG data and then, a short period 
of time later, commencing palpation of the first tender point. 
Preferably, the period of time between the commencement of 
data acquisition and the commencement of palpation of the 
first tender point may be between one and three hundred 
seconds. Palpation of the first tender point may be accom 
plished by pressing on the tender point with an algometer, 
preferably at a rate of approximately one kilogram per centi 
meter squared per second, until the Subject reports a painful 
sensation. Preferably, palpation pressure may be removed as 
Soon as the Subject reports a painful sensation. A record is 
made of the amount of the pressure being applied at the 
moment the Subject reports a painful sensation. Although the 
TPPEEG record may be obtained while the subject’s eyes are 
closed, it should not be confused with the “eyes closed EEG 
record described above. 
0065. Further according to the TPP test method, the acqui 
sition of the TPP EEG record may include continued record 
ing of EEG data (with the subject’s eyes closed) for a period 
of time after release of palpation pressure, preferably between 
1 and 300 seconds, and most preferably, for at least 60 sec 
onds. A comparison may then be made between EEG data 
collected before application of palpation pressure and EEG 
data collected after release of palpation pressure. This com 
parison may then be used to make diagnostic findings. Such 
findings may include changes in brain EEG activity, when 
comparing EEG after release of palpation pressure to EEG 
before palpation pressure, in specific regions of the brain 
characteristic of a brain-related chronic pain condition, but 
not otherwise anticipated in a healthy normal individual. 
0066 Following this period, a second and subsequent ten 
der point may be serially palpated, preferably with an algo 
meter, in the same manner as described for the first, with TPP 
EEG records being recorded for each by recording the eyes 
closed EEG for each site in the manner described with regard 
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to obtaining the TPPEEG record for the first site. This process 
may be repeated for each chosen tender point. Accordingly, 
the resulting EEG data record includes the TPP EEG records 
acquired for each chosen tender point. 
0067. The “TPP” EEG records may be acquired for a 
period of time that is sufficient to extract from each “TPP 
EEG record a minimum of 60 seconds of “clean EEG data, 
that is, data free of extraneous electrical noise Such as that 
from electromyographic movement. Preferably, all EEG 
records (“eyes open EEG records, “eyes closed EEG 
records, and “TPP” EEG records) may be individually edited 
to provide from each EEG record a minimum of 60 seconds of 
clean EEG. Preferably, the clean data is obtained so as to 
present a high degree of statistical consistency. Such mea 
sures as “Split-Half reliability, which is the ratio of variance 
between the even and odd seconds of the time series of 
selected clean EEG, and “Test Re-test” reliability, which is 
the ratio of variance between the first half and the second half 
of the selected clean EEG segments may be used. Preferably, 
clean EEG data is obtained such that measures of these ratios 
are a minimum of 0.95 and 0.90 respectively, which is con 
sistent with levels of reliability commonly published in EEG 
literature. 
0068. With regard to the TPP test method, clean data 
includes that EEG data acquired after palpation of a tender 
point, and does not include any EEG data acquired during the 
palpation of a tender point. In addition, to assess the stability 
of a TPP EEG record, EEG data acquired before palpation of 
a tender point may be removed, edited and statistically com 
pared to like data in the “eyes closed EEG record obtained 
from the eyes closed EEG test. Stability of the “closed eyes’ 
and TPPEEG records is indicated by a finding that there is no 
statistically significant difference between the “eyes closed 
EEG record and the pre-palpation portion of the. TPP EEG 
record. A contrary finding indicates instability and a need to 
repeat the EEG tests. 
0069. Further to the method, and in the preferred embodi 
ment, clean “eyes open”, “eyes closed”, and “PPT EEG 
records may be then mathematically analyzed for various 
time domain and frequency domain parameters of their 
respective electrical signals. These analyses may include, but 
are not limited to Voltage and current analyses, frequency 
spectrum analyses using methods such as a Fast Fourier 
Transform or wavelet analysis, an absolute power analysis, a 
relative power analysis, a phase analysis, a coherence analy 
sis, an amplitude asymmetry analysis, and localization of 
electrical activity in the brain using inverse EEG computation 
analysis. 
0070 Findings from the aforementioned analyses may 
then be statistically compared to the same parameters deter 
mined from “eyes open”, “eyes closed”, and “PPT EEG 
records taken from an age and gender matched database of 
healthy normal individuals. Such statistical analyses may 
include, but are not limited to deviations from a standard 
normal distribution. Findings of Statistically significant 
abnormal deviation, or lack thereof, may then be presented in 
a graphical or numerical format for analysis by a competent 
health care professional or person of similar expertise. 
(0071 EEG abnormalities consistent with those observed 
in a sample population of fibromyalgia patients may include, 
but are not limited to one or more of the following: (1) an 
overall reduction in EEG power across all spectra in either of 
the eyes open or eyes closed conditions; (2) statistically sig 
nificant low EEG power levels in frontal or temporal regions 
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of any of the delta (1-3.5 hertz), theta (4-7.5 hertz) or alpha 
(8-12 hertz) frequency segments of EEG for the eyes closed 
condition; (3) statistically significant low coherence among 
the frontal EEG sites for the delta or theta EEG segments in 
either of the eyes closed or eyes open conditions; (4) statisti 
cally significant high relative beta (12.5-25 hertz) absolute 
power in the parietal region of the brain for either of the eyes 
closed or eyes open conditions. The magnitude of statistical 
variation considered to be statistically "significant may vary 
depending on the application. For example, in research, a 
difference between a sample and a population measure gen 
erally has to have a p-value of 0.01 or less for the difference to 
be considered statistically “significant'. However, in clinical 
application statistically significant differences may be 
declared with p-values at the 0.1 level or less. 
0072 Further EEG abnormalities consistent with those 
observed in a sample population offibromyalgia patients, and 
drawn particularly to the TPP test method, may include but 
are not limited to a finding of (1) a statistically significant 
increase in EEG absolute power, particularly in the alpha and 
beta segments, in the parietal and occipital areas of the brain 
as compared to the “eyes closed EEG record (“eyes closed 
EEG findings without tender point palpation) for the same 
Subject; or (2) a statistically significant increase in coherence 
in the alpha or beta segment of EEG. 
0073. A diagnosis of fibromyalgia may be made when 
physical assessment findings that Support a diagnosis of 
fibromyalgia are augmented by (1) at least one abnormal 
finding resulting from the TPP test, preferably a finding of a 
statistically significant increase in EEG absolute power, and 
particularly in the alpha and beta segments, in the parietal and 
occipital areas of the brain as compared to the eyes closed 
findings without tender point palpation for the same subject; 
and preferably (2) at least one abnormal finding resulting 
from the eyes closed EEG test, preferably statistically signifi 
cant low EEG power levels in frontal or temporal regions of 
any of the delta, theta or alpha frequency segments of EEG for 
the eyes closed condition, and most preferably with an addi 
tional finding of statistically significantlow coherence among 
the frontal EEG sites for the delta or theta EEG segments. 
0074 Clean EEG records from a subject may be math 
ematically analyzed for various time domain and frequency 
domain parameters of their electrical signals, consistent with 
analysis techniques already described, and then findings from 
these mathematical analyses may be statistically compared to 
like parameters taken from an age and gender matched data 
base of individuals known to have fibromyalgia. The statisti 
cal comparisons may include, but are not limited to deviations 
from a standard normal distribution of like EEG measures 
associated with members of a database of individuals known 
to have fibromyalgia. The results of those comparisons may 
then be presented in a graphical or numerical format for 
analysis by a competent health care professional or person of 
similar expertise for the existence of Statistically significant 
abnormal deviations, or the lack thereof. A finding in Support 
of a fibromyalgia diagnosis would be supported if there is an 
absence of any significant deviation between measures from 
a subjects clean EEG and those from a database comprising 
individuals known to have fibromyalgia. 
0075 Similarly, clean EEG from a subject may be math 
ematically analyzed for various time domain and frequency 
domain parameters of its electrical signals, consistent with 
analysis techniques already described, and then findings from 
these mathematical analyses may be statistically compared to 
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like parameters determined from an age and gender matched 
database of individuals known to have a chronic pain condi 
tion other than fibromyalgia. 
0076. The statistical comparisons may include, but are not 
limited to deviations from a standard normal distribution of 
like EEG measures associated with members of a database of 
individuals known to have the chronic pain condition. The 
results of those comparisons may then be presented in a 
graphical or numerical format for analysis by a competent 
health care professional or person of similar expertise for the 
existence of statistically significant abnormal deviations, or 
the lack thereof. A finding in Support of a chronic pain con 
dition diagnosis would be supported if there is an absence of 
any significant deviation between measures from a subjects 
clean EEG and those from a database comprising individuals 
known to have the chronic pain condition. 
0077. To determine the probability that a subject belongs 
to a population of individuals Suffering from fibromyalgia a 
statistical comparison may be made of EEG parameters of the 
Subject, as determined from the aforementioned analyses, to 
like EEG parameters determined from a database of individu 
als known to suffer from fibromyalgia. The statistical com 
parison may include, but is not limited to, determination of 
Z-Statistics associated with specific EEG measures from a 
standard normal distribution determined from the database of 
individuals known to suffer from fibromyalgia. Probability of 
inclusion in the population of individuals Suffering from 
fibromyalgia would result from findings that Subject mea 
Sures cannot be excluded from the database standard normal 
distribution. Assuming that the data in the database of fibro 
myalgia patient EEG is normally distributed, then statistics 
Such as the t-statistic or the Z-Statistic can be used to deter 
mine the probability that the sample EEG belongs to the 
population of fibromyalgia sufferers. If the probability is 
sufficiently low (e.g. p-0.01) then a conclusion could be 
made that the sample does not belong to that population. 
0078 Similarly, the probability that a subject belongs to 
the population of individuals suffering from a chronic pain 
condition other than fibromyalgia may be determined by 
making statistical comparison of EEG parameters of a Sub 
ject, determined from the aforementioned analyses, to like 
EEG parameters determined from a database of individuals 
known to suffer from that chronic pain condition. The statis 
tical comparison may include, but is not limited to, determi 
nation of Z-statistics associated with specific EEG measures 
from a standard normal distribution determined from the 
database of individuals known to suffer from the chronic pain 
condition. Probability of inclusion in the population of indi 
viduals Suffering from the chronic pain condition other than 
fibromyalgia would result from findings that Subject mea 
Sures cannot be excluded from the database standard normal 
distribution. 
0079. In addition, findings from aforementioned analyses 
of clean EEG records from a subject may be statistically 
correlated to measures of symptom severity. As previously 
described, analysis findings may be mathematically analyzed 
for various time domain and frequency domain parameters of 
their electrical signals. A number of measures of the magni 
tude of deviation from standard normal distributions of either 
healthy normal EEG, known fibromyalgia patient EEG, or 
from EEG of individuals known to suffer from a chronic pain 
condition other than fibromyalgia can be determined. The 
magnitudes are presumed to be related to the severity of the 
condition, and may be statistically correlated to Such symp 
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tom measures that may include, but are not limited to tender 
point pain pressure thresholds as determined by an algometer, 
and various other indices of pain derived from the algometry 
measures (e.g. the sum of all 18 tender point pain tolerance 
measures, the average of all 18 tender point pain tolerance 
measures, etc.). Such analysis has utility in both predicting 
symptom severity in individuals with fibromyalgia, and in 
determining the effect of therapeutic intervention to corrector 
manage symptoms of fibromyalgia. 
0080. Also the above-described EEG testing and statisti 
cal analysis methods may be repeated on a subject following 
a period of therapeutic intervention on the subject. The results 
of these statistical analyses may be statistically compared to 
like statistical analyses of the subject accomplished before 
therapeutic intervention was started. This comparison might 
include, but is not be limited to, paired t-testing statistics, 
correlation analysis of changes in Symptom severity, and 
Subsequent comparison to a database of age and gender 
matched healthy normal individuals. The comparisons could 
be used as a means of assessing the effectiveness of a chosen 
therapeutic intervention, or as a means of determining if an 
alternate intervention may be indicated in the absence of 
treatment effect from a current therapeutic intervention. The 
comparisons could also be used as a means of determining if 
further therapeutic intervention may be indicated in the 
absence of any abnormal findings. With regard to the TPP test, 
repeat testing may include applying tender point pressure 
with an algometer only to the levels required to cause a 
painful response recorded in the same testing performed 
before therapeutic intervention. 
0081 EEG data may be acquired from a subject at a first 
location (e.g. a clinical location) and the EEG data may be 
transferred via electronic means to another location (e.g. a 
central analysis location) for the herein described analysis 
and statistical comparisons. The electronic means of data 
transfer may include, but is not be limited to, data transfer 
across a local area network or the internet. Analyses and 
statistical findings may then be transferred from the central 
analysis location to the clinical location where they can be 
used in various ways by a physician or similarly qualified 
health care professional for the determination of best clinical 
practice and therapeutic intervention. 
0082 EEG data may also be acquired from a subject at a 
first location (e.g. a clinical location) and the EEG data trans 
ferred via electronic means to another location (e.g. a central 
analysis location) for the purpose of increasing the size of 
various databases of individuals known to be suffering from 
fibromyalgia, individuals known to be suffering from a 
chronic pain condition other than fibromyalgia, and/or 
healthy normal individuals. 
0083. In testing for chronic pain conditions other than 
fibromyalgia, other, more general physical tests may be per 
formed. Some of those tests may include a form of tender 
point palpation that differs from that typically done in testing 
for fibromyalgia, and that differs in a way that makes the 
testing more useful in diagnosing other chronic pain condi 
tions. For example, tests involving algometer palpation may 
be performed at several points on the body of a suspected 
ICLBP patient, but not necessarily at the same 18 tender 
points described above for diagnosing and/or assessing fibro 
myalgia. Testing for ICLBP may include some other form of 
tender point palpation including physical action that causes 
reproduction of the back pain. Just as in the method disclosed 
for diagnosing and/or assessing fibromyalgia, this general 
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physical test may be done following a period of EEG collec 
tion, and then additional EEG data may be captured after the 
test. Further, just as in the method disclosed for diagnosing 
and/or assessing fibromyalgia, differences in the EEG data 
may then be analyzed and/or statistically compared to deter 
mine if the result belongs to a particular chronic pain condi 
tion such as ICLBP. For example, the ideal test for an ICLBP 
patient might include palpation of four FM tender points and 
performance of a number of other physical actions that cause 
reproduction of pain specific to ICLBP patients. If the EEG 
analysis then shows a negative finding for the fibromyalgia 
tender points but a positive finding for the back pain actions, 
then a conclusion that the patient has ICLBP would be sup 
ported rather than a conclusion that the patient is Suffering 
from fibromyalgia. 
I0084. With reference to FIGS. 2-4, a method is provided 
for diagnosing or assessing central pain such as that arising 
from abnormal brain function, including but not limited to, 
central sensitivity and abnormal network connectivity 
involved in pain processing. The method includes assessing a 
human Subject’s brain function and then determining the 
probability that the subject is suffering from central pain by 
obtaining a quantitative assessment of the Subject’s brain 
function and making a statistical comparison between the 
Subject’s quantitative brain function assessment and one or 
more databases of quantitative assessments of the brain func 
tions, such as a database of individuals known to be suffering 
from central pain, a database of individuals known to be 
suffering from pain that is not central pain, or a database of 
healthy normal individuals. 
I0085. The assessment of a subject's brain function may 
include obtaining a neuroimaging test Such as, but not limited 
to, magnetic resonance imaging, computer aided tomogra 
phy, positron emission tomography, or single photon emis 
sion computed tomography, and may also include brain elec 
trical function tests such as electroencephalography or 
magnetoencephalography. The determination of the prob 
ability that the Subject is Suffering from central pain may 
include determining the probability that the subject is suffer 
ing from central pain by obtaining a quantitative assessment 
of the Subject's neuroimaging test and making a statistical 
comparison between the quantitative assessment and a data 
base of like quantitative assessments of healthy individuals, 
individuals known to be suffering from central pain, or indi 
viduals suffering from pain that is not central pain. 
I0086 A physical assessment may first be performed of a 
human Subject presenting with a complaint of symptoms 
characteristic of central pain, Such as chronic pain with no 
clear etiology. The physical assessment may include, among 
other things, a determination of chronic widespread pain, 
sleep difficulty, fatigue, cognitive difficulty and other symp 
toms associated with abnormal brain function involved in 
central pain. In the absence of a definitive diagnosis, a diag 
nostic or assessment test for central pain may be performed in 
accordance with the present invention. 
I0087. The method may include the step of assessing the 
brain function of a subject to determine the presence of cen 
tral pain, whereas the step includes, but is not limited to, 
making measures of a brainactivities, e.g., of a brainfunction, 
brain conditions or brain anatomy, either by direct assessment 
techniques known in the art Such as neuroimaging, or by 
indirect assessment Such as analysis of other biological mea 
Sures. The assessment step includes use of any method known 
in the art to determine the presence of any brain activity 
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known to be associated with central pain, including but not 
limited to, central sensitivity or abnormal levels of network 
connectivity. One skilled in the art of medical assessment may 
administer and interpret one or more assessments designed to 
detect central pain. Such assessments may include any one or 
more known neuroimaging tests. Such assessments may also 
be used for detecting the presence and identifying the location 
of one or more abnormal brain activities through interpreta 
tion. 
0088. In a preferred embodiment, a means of assessing a 
brain to determine the presence of central pain in a subject 
includes the use of one or more neuroimaging tests utilizing 
methods and apparatuses known in the art, with the neuroim 
aging tests being performed before, during and after the appli 
cation of any one or more forms of sensory stimulation (SS) 
intended to cause a brain response. A neuroimaging test per 
formed before an SS is henceforth referred to as a “baseline' 
neuroimaging test. A neuroimaging test performed after an 
SS is henceforth referred to as a “post-SS neuroimaging test. 
The combination of neuroimaging tests and application of 
one or more sensory stimulations is henceforth referred to as 
a “brain response test' (BRT). The SS includes any noxious, 
pain inducing or non-painful means. In a preferred embodi 
ment, a BRT may include an electroencephalogram (EEG) 
test performed with eyes closed or eyes open, with at least one 
additional EEG record made that includes EEG data obtained 
during and after the application of any one or more forms of 
an SS. 
I0089. One embodiment of an SS is palpation of tender 
points on the subjects body, consistent with the method 
described herein as a tender point test. Other means of caus 
ing a painful or noxious SS for the purposes of a BRT may 
include, but are not limited to, application of mechanical 
pressure on any part of the body, application of otherforms of 
mechanical stimulation to any part of the body (e.g. a 
"pinch'), application of an electrical stimulus, application of 
aheat-producing stimulus, and in vivo or in vitro introduction 
of a chemical agent meant to elicit a painful or non-painful 
response. Means of causing a non-painful SS for the purposes 
of a BRT may include, but are not limited to, forms of typi 
cally non-painful physical contact including mechanical 
brushing, controlled physical movements made by the Sub 
ject, and various forms of mental processing Such as cognitive 
exercises. 
0090. Further to the application of an SS, the method 
includes any number of applications of stimulation to elicit 
any number of brain responses. For example, a single SS may 
be applied to produce a single brain response. Alternately, a 
series of SS applications may be made over a period of time to 
produce multiple brain responses so that a BRT may include 
assessing changes in brain response over time. Such series of 
PS applications may include one or more applications of any 
combination of noxious, painful or non-painful stimuli, with 
a period of rest between each application ranging from one 
second to several minutes. Such assessment of changes in 
brain response may include, but are not limited to, quantifi 
cation of temporal Summation of pain, also known in the pain 
literature as “wind up'. 
0091. The BRT test may be executed by acquiring a brain 
response record using any means of neuroimaging test. In a 
preferred embodiment, a brain response test EEG (“BRT 
EEG') record is obtained that includes EEG data obtained for 
a period of time before, during, and after the application of 
any number of an SS. EEG data may be obtained from EEG 
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electrode sites for a period of time, preferably ranging from 
one second to 15 minutes, prior to commencement of a first 
SS. During application of an SS, EEG data obtained may be 
denoted as EEG collected during application of the SS. Data 
collected during application of an SS may have unwanted 
aspects. For example, EEG data collected during the applica 
tion of an SS may also contain measurements of electromyo 
graphic signals arising from muscle contractions a patient 
may make as a result of feeling a sensation Such as pain. 
Accordingly, the data collected during the application of an 
SS may or may not be removed in Subsequent analysis 
according to the method. Further to the embodiment, EEG 
data may be obtained from EEG electrode sites for a period of 
time, preferably ranging from one to 15 minutes, after appli 
cation of an SS. 
0092. Further to the BRT test method, a record is made 
quantifying parameters associated with the one or more SS 
being used. For example, if an SS involves palpation of a 
tender point, then the location and amount of mechanical 
pressure being applied at or near the time the Subject reports 
a painful sensation may be recorded. Other examples of quan 
tification of an SS may include, but are not limited to, the 
amount of pressure on any body part required to elicit pain, 
parameters of other forms of mechanical stimuli, parameters 
of forms of electrical stimuli, parameters of forms of heat 
stimuli, parameters of an introduced chemical agent, param 
eters of brush strokes and parameters of a mental exercise. 
(0093. Further to the BRT test method, the recording of 
EEG may continue for a period of time after completion of 
each of the one more SS applications, including a final SS 
application, with the period of time preferably being between 
one second and 15 minutes. The process of application of an 
SS and subsequent recording of EEG may be repeated until all 
intended applications of an SS are completed. Accordingly, 
the resulting EEG data record includes the BRT EEG records 
for all applications of SS. 
(0094. The BRT EEG records may be acquired for a period 
of time that is sufficient to extract from each BRT EEG record 
a record of “clean EEG data, that is, EEG data that have 
minimal non-EEG signals such as extraneous electrical noise 
arising from, for example, instrumentation anomalies or elec 
tromyographic movement. Preferably, a record of clean EEG 
data is sufficient to provide enough EEG data to perform any 
one of a number of EEG analyses known in the art with a 
sufficiently high degree of statistical confidence. More pref 
erably, all EEG records according to the method may be 
individually edited to provide from each EEG record a period 
comprising a minimum of 60 seconds of clean EEG. With 
regard to the BRT test method, clean data preferably does not 
include any EEG data acquired during the application of an 
SS. 
(0095. Further to the BRT test method, and in the preferred 
embodiment, clean EEG records may be then mathematically 
analyzed for various time domain and frequency domain 
parameters of their respective electrical signals. These analy 
ses may include, but are not limited to Voltage analysis, cur 
rent analysis, Voltage and current analysis, frequency spec 
trum analysis using Fast Fourier Transform (FFT) analysis, 
frequency spectrum analysis using a wavelet analysis 
method, frequency spectrum analysis using absolute power 
analysis method, frequency spectrum analysis using relative 
power analysis method, frequency spectrum analysis using 
phase analysis method, frequency spectrum analysis using 
coherence analysis method, frequency spectrum analysis 
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using amplitude symmetry analysis method, phase analysis, 
various forms of network analysis and source localization of 
electrical activity in the brain using inverse EEG computation 
analysis. The purpose of Such analyses is to determine the 
presence of one or more abnormal brain activities, e.g., brain 
function, brain condition, brain anatomy or related brain mea 
Sures that indicate central pain Such as, but not limited to, 
central sensitivity and abnormal levels of network connectiv 
ity. 
0096. According to the BRT test method, a finding of 
central pain is made by analyzing findings from the afore 
mentioned BRT analyses. Such findings may include, but are 
not limited to, a determination of a brain activity associated 
with central sensitivity or abnormal brain network connectiv 
ity associated with pain processing. In a preferred embodi 
ment, BRT EEG records may be statistically compared to the 
same parameters determined from EEG records taken from 
age and gender matched databases of either healthy normal 
individuals or individuals that are suffering from pain that is 
not central pain. Such statistical analyses may include, but are 
not limited to deviations from a standard normal distribution. 
Findings of statistically significant abnormal deviation, or 
lack thereof, may then be presented in a graphical or numeri 
cal format for analysis by a competent health care profes 
sional or person of similar expertise. 
0097 EEG abnormalities consistent with subjects suffer 
ing from central pain may include measures indicative of 
central sensitivity or abnormal network connectivity includ 
ing, but not limited to one or more of the following: (1) 
abnormal levels of in EEG power in spectral segments of 
resting EEG measures, including but not limited to, an abnor 
mal level of EEG power across the entire resting EEG spectra; 
(2) abnormal levels of coherence or phase shift between at 
least two resting EEG sites; (3) abnormal levels of resting 
EEG relative power in particular regions of the brain. 
0098. Further EEG abnormalities consistent with subjects 
Suffering from central pain, and drawn particularly to the 
EEG BRT test method, may include but are not limited to a 
finding of (1) statistically significant increases in EEG abso 
lute power, particularly in the alpha and beta segments, in the 
parietal, occipital, and temporal areas of the brain as com 
pared to the resting EEG record for the same subject; or (2) 
statistically significant increases in coherence in spectral seg 
ments of the BRT EEG record as compared to the resting EEG 
record for the same subject. 
0099. A determination of central pain may be made when 
physical assessment findings that Supporta diagnosis of cen 
tral pain are augmented by assessing a brain following a BRT. 
The assessment of a BRT may include a statistical compari 
son between any one or more of the subjects BRT measures 
and a database of like BRT measures of either healthy normal 
individuals, individuals suffering from pain that is not central 
pain, or individuals suffering from central pain. Alternately, 
central pain may be diagnosed by Statistically determining 
one or more deviations between a subjects one or more BRT 
measures and like BRT measures obtained from at least one 
healthy normal individual or at least one individual suffering 
from pain that is not central pain; then comparing the one or 
more deviations to like deviations detected in a sample popu 
lation of Subjects known to be suffering from central pain. 
0100. In a preferred embodiment, clean resting EEG or 
BRT EEG records from a subject may be mathematically 
analyzed for various time domain and frequency domain 
parameters of their electrical signals, consistent with analysis 
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techniques already described, and then findings from these 
mathematical analyses may be statistically compared to like 
parameters taken from age and gender matched databases of 
either healthy normal individuals, individuals suffering from 
pain that is not central pain, or individuals known to be 
Suffering from central pain. The statistical comparisons may 
include, but are not limited to deviations from a standard 
normal distribution of like EEG measures associated with 
members of databases of healthy normal individuals, indi 
viduals suffering from pain that is not central pain, or indi 
viduals known to be suffering from central pain. The results 
of those comparisons may then be presented in a graphical or 
numerical format for analysis by a competent health care 
professional or person of similar expertise for the existence of 
statistically significant abnormal deviations, or the lack 
thereof. A central pain diagnosis would be Supported if one or 
more findings of either resting EEG or BRT EEG records are 
consistent with like findings from a database comprising indi 
viduals known to be suffering from central pain. More pref 
erably, a central pain diagnosis would be Supported if one or 
more findings of either resting EEG or BRT EEG records are 
consistent with statistical significance to like findings from a 
database comprising individuals known to be suffering from 
central pain. 
0101. Further according to the BRT test method, measures 
of an abnormal brain activity, e.g., brain function, brain con 
dition, brain anatomy or related brain measures arising from 
analyses of BRT test findings from a subject may be corre 
lated to measures of symptom severity, such as but not limited 
to pain severity. Such correlation may be used to create math 
ematical correlation models such as a mathematical model 
that provides for symptom severity as a function of measures 
of brain activities, or such as the effect of a therapeutic inter 
vention as a function of measures of brain activities. Such 
mathematical correlation models may subsequently be used 
to predict symptom severity in individuals having central 
pain, or to determine the effect of atherapeutic intervention to 
alleviate symptoms of central pain, when measures of brain 
activities are known. 
0102. Further, BRT test analyses according to the method 
may also be used for determining the location of abnormal 
brain activity and further for determining points for applica 
tion of therapeutic methods for alleviating central pain, 
including but not limited to, cortical stimulation methods. 
0103) Further, BRT testing and statistical analysis meth 
ods may be repeated on a subject following a period of thera 
peutic intervention on the Subject for alleviating central pain, 
including but not limited to, cortical stimulation methods. 
The results of these repeat statistical analyses may be statis 
tically compared to like statistical analyses of the Subject 
accomplished by performing BRT testing before therapeutic 
intervention was started. This comparison might include, but 
is not be limited to, paired t-testing statistics, correlation 
analysis of changes in Symptom severity, and Subsequent 
comparison to databases of either healthy normal individuals, 
individuals suffering from pain that is not central pain, or 
individuals known to be suffering from central pain. The 
comparisons could be used as a means of assessing the effec 
tiveness of a chosen therapeutic intervention, or as a means of 
determining if an alternate intervention may be indicated in 
the absence of treatment effect from a current therapeutic 
intervention. The comparisons could also be used as a means 
of determining if further therapeutic intervention may be 
indicated in the absence of any abnormal findings. With 
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regard to the BRT test, repeat testing may include the appli 
cation of one or more SS forms. The application of the one or 
more SS forms may be done in accordance with types and 
parameters quantified for the same form of SS that was used 
or performed before therapeutic intervention. 
0104 Further according to the method, BRT test method 
data may be acquired at a first location (e.g. a clinical loca 
tion) and the acquired BRT test method data transferred via 
electronic means to another location (e.g. a central analysis 
location) for the herein described analysis and statistical com 
parisons to be accomplished. The electronic means of data 
transfer may include, but isn't limited to means of data trans 
fer across a local area network and/or the internet. Conse 
quently, analysis and statistical findings may then be trans 
ferred from a central analysis location to a clinical location, 
where they may be used in various ways by a physician or 
similarly qualified health care professional for the diagnosis 
or assessment of central pain. 
0105. Further according to the method, BRT test method 
data may be acquired at a first location (e.g. a clinical loca 
tion) and the acquired BRT test method data transferred via 
electronic means to another location (e.g. a central analysis 
location) for a purpose such as inclusion or increasing the size 
of various databases of individuals known to be suffering 
from central pain, individuals known to be suffering from 
pain that is not central pain, and healthy normal individuals. 
0106 The method of diagnosis and assessment described 
herein may be accomplished with any number of apparatuses 
that include apparatuses for providing a neuroimaging test 
and apparatuses that may be required to create a sensory 
stimulation. Referring to FIG. 5, a preferred embodiment of 
an apparatus 5 for diagnosing and assessing central pain may 
include a neuroimaging device 1 configured to sense and 
generate images representing central nervous system func 
tion, and operably connected to a computing device 2 such as 
a computer in a way that permits data transfer between the 
neuroimaging device 1 and the computing device 2. Such 
connection may be accomplished via a physical cable con 
nection 4 or alternately via a wireless transfer means. The 
apparatus 5 for diagnosing and assessing central pain may 
further include a sensory stimulation device 3 configured to 
stimulate brain activities associated with central sensitivity, 
and further operably connected to a computing device 2 in a 
way that permits data transfer between the sensory stimula 
tion device 3 and the computing device 2. Such connection 
may also be accomplished via a physical cable connection 6 
or alternately via a wireless transfer means. In practice, the 
apparatus 5 for diagnosing and assessing central pain is con 
figured to accomplish the BRT test method described herein. 
In one embodiment, the computing device 2 may be pro 
grammed to operate the neuroimaging device 1 for a period of 
time, and to collect data, in accordance with the BRT test 
method, from the neuroimaging device 1 during that time. 
After such period of time, the computing device 2 is further 
programmed to Suspend data collection from the neuroimag 
ing device 1 and to direct use of a sensory stimulation appa 
ratus 3. Such directing of use may include signaling an opera 
tor to manually use a sensory stimulation apparatus 3 on a 
Subject, or may also include programming that automatically 
controls and operates a sensory stimulation apparatus 3 to 
create a sensory stimulation on a Subject. After use of the 
sensory stimulation apparatus 3, the computing device 2 may 
be programmed to further operate the neuroimaging device 1 
for another period of time, and to collect additional data in 
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accordance with the BRT test method from the neuroimaging 
device 1 during that additional period of time. Using neu 
roimaging device 1 data gathered during both periods of time, 
the computing device 2 may be further programmed to per 
form statistical analyses and comparisons on the data in 
accordance with the BRT test method, and further to transmit 
data across a network, all according to the method of diagno 
sis and assessment described herein. 
0107 The invention is not limited in any way to the 
embodiments disclosed herein. In this regard, no attempt is 
made to show structural details of the disclosed apparatuses 
or process details of the disclosed methods in more detail than 
is necessary for a fundamental understanding of the disclosed 
apparatuses and methods. The description is intended only to 
make apparent to those skilled in the art how the several forms 
of the invention may be embodied in practice. 
1-52. (canceled) 
53. A method for diagnosing and assessing central pain, the 
method including the steps of 
assessing a subject’s brain function using a brain response 
test (BRT) comprising the steps of: 
performing one or more baseline neuroimaging tests, 
causing one or more brain responses by applying one or 
more sensory stimulations, and 
performing one or more neuroimaging tests after the 
step of causing one or more brain responses; 
obtaining a quantitative assessment of the Subject's brain 
function; and 
making a statistical comparison between the Subjects 
quantitative brain function assessment and one or more 
databases of quantitative assessments of the brain func 
tions. 
54. The method of claim 53 in which the step of making a 
statistical comparison includes making a statistical compari 
son between the Subject’s quantitative brain function assess 
ment and the one or more databases of quantitative assess 
ments of brain functions where the one or more databases 
include a database of individuals known to be suffering from 
central pain, a database of individuals known to be suffering 
from pain that is not central pain, or a database of healthy 
normal individuals. 
55. The method of claim 53 in which the step of applying 
one or more sensory stimulations includes the application of 
any noxious, or pain inducing or non-painful means of sen 
sory stimulation causing one or more brain responses. 
56. The method of claim 53 in which the step of performing 
one or more baseline neuroimaging tests includes performing 
an electroencephalogram (EEG) test. 
57. The method of claim 55 in which the step of applying 
one or more sensory stimulations includes selecting for appli 
cation one or more sensory stimulations from the group of 
sensory stimulations consisting of a tender point test, appli 
cation of mechanical pressure on any part of the body, appli 
cation of otherforms of mechanical stimulation to any part of 
the body, application of an electrical stimulus, application of 
a heat-producing stimulus, in vivo or in vitro introduction of 
a chemical agent, mechanical brushing, controlled physical 
movements made by the Subject, or forms of mental process 
ing Such as cognitive exercises. 
58. The method of claim 53 in which the step of applying 
one or more sensory stimulations includes applying a series 
of sensory stimulations that are made over a period of time in 
Such a way as to produce multiple brain responses. 
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59. The method of claim 53 in which the step of using a 
BRT includes assessing changes in brain response over a 
period of time. 
60. The method of claim 53 in which the step of obtaining 
a quantitative assessment of the Subject's brain function 
includes assessing changes in brain function in response to a 
sensory stimulation. 
61. The method of claim 56 in which performance of an 
EEG test includes the steps of: 
obtaining EEG data for a period of time before the appli 
cation of a sensory stimulation; 
obtaining EEG data and after the application of any one or 
more sensory stimulations; and 
performing a mathematical analysis of obtained EEG data. 
62. The method of claim 61 in which each step of obtaining 
EEG data occurs over a period of time between approxi 
mately one second to 15 minutes. 
63. The method of claim 53 in which the step of using a 
BRT test includes the step of quantifying and recording 
parameters associated with the one or more sensory stimula 
tions. 
64. The method of claim 63 in which the step of quantifying 
and recording parameters occurs at or near the time the Sub 
ject reports a painful sensation. 
65. The method of claim 63 in which the step of quantifying 
and recording parameters includes quantifying and recording 
parameters that are selected from a group consisting of loca 
tion of mechanical pressure, amount of mechanical pressure, 
parameters of other forms of mechanical stimuli, parameters 
of forms of electrical stimuli, parameters of forms of heat 
stimuli, parameters of an introduced chemical agent, param 
eters of brush strokes, or parameters of a mental exercise. 
66. The method of claim 61 in which the performance of an 
EEG test includes the step of recording EEG for a period of 
time after application of a final sensory stimulation. 
67. The method of claim 66 in which the step of recording 
EEG for a period of time after application of a final sensory 
stimulation occurs over a period of time between approxi 
mately one second and 15 minutes. 
68. The method of claim 66 in which the performance of an 
EEG test includes the step of producing a resulting EEG data 
record that includes the brain response test EEG records 
following each one or more applications of one or more 
sensory stimulations. 
69. The method of claim 68 in which the step of producing 
a resulting EEG data record includes the step of providing 
clean EEG data sufficient to perform an EEG analysis, and 
doing so by extracting non-EEG signals and EEG data 
acquired during the application of any one or more sensory 
stimulations from each EEG record. 
70. The method of claim 61, in which the step of perform 
ing a mathematical analysis is performed on a resulting EEG 
data record. 
71. The method of claim 61, in which the step of perform 
ing a mathematical analysis includes the step of selecting one 
or more analyses from a group consisting of time domain and 
frequency domain parameters. 
72. The method of claim 61, in which the step of perform 
ing a mathematical analysis includes the step of selecting one 
or more analyses from a group consisting of Voltage analysis, 
current analysis, Voltage and current analysis, frequency 
spectrum analysis using Fast Fourier Transform (FFT) analy 
sis, frequency spectrum analysis using a wavelet analysis 
method, frequency spectrum analysis using absolute power 
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analysis method, frequency spectrum analysis using relative 
power analysis method, frequency spectrum analysis using 
phase analysis method, frequency spectrum analysis using 
coherence analysis method, frequency spectrum analysis 
using amplitude symmetry analysis method, phase analysis, 
various forms of network analysis and source localization of 
electrical activity in the brain using inverse EEG computation 
analysis. 
73. The method of claim 53 in which the step of making a 
statistical comparison includes the step of performing a math 
ematical analysis to determine one or more brain measures to 
Support a diagnosis of the presence of one or more brain 
activities associated with central pain. 
74. The method of claim 73, in which the step of perform 
ing a mathematical analysis to determine one or more brain 
measures to Support a diagnosis of the presence of one or 
more brain activities associated with central pain includes the 
step of analyzing findings from one or more BRT tests. 
75. The method of claim 74, in which the step of analyzing 
findings from one or more BRT tests includes performing one 
or more analyses to discover one or more brain activities 
associated with central sensitivity or abnormal brain network 
connectivity associated with pain processing. 
76. The method of claim 74, in which the step of analyzing 
findings from one or more BRT tests includes the step of 
statistically comparing findings of a BRT test to BRT test 
records taken from either healthy normal individuals, indi 
viduals Suffering from central pain, or individuals that are 
suffering from pain that is not central pain. 
77. The method of claim 74 in which the step of performing 
a mathematical analysis includes making a determination of 
EEG abnormalities selected from the group of abnormalities 
consisting of abnormal levels of EEG power, abnormal levels 
of coherence between at least two EEG sites, abnormal levels 
of phase shift between at least two EEG sites, or abnormal 
levels of EEG relative power in particular regions of the brain. 
78. The method of claim 53, in which the method for 
diagnosing and assessing central pain further includes aug 
menting assessment of a brain following a BRT by making a 
physical assessment. 
79. The method of claim 74 including the step of diagnos 
ing central pain by: 
statistically determining one or more deviations between a 
subjects one or more BRT measures and like BRT mea 
sures obtained from at least one healthy normal indi 
vidual or at least one individual suffering from pain that 
is not central pain; then 
comparing the one or more deviations to like deviations 
detected in a sample population of Subjects known to be 
Suffering from central pain. 
80-88. (canceled) 
89. The method of claim 53, in which the step of diagnos 
ing and assessing central pain further includes the step of 
determining that at least one abnormal measure of the Sub 
ject's brain associated with central pain corresponds to at 
least one statistically significant difference finding of a BRT 
teSt. 
90-97. (canceled) 
98. The method of claim 53 in which the step of assessing 
a subject’s brain function further includes the step of making 
brain measures to identify the presence of one or more brain 
activities associated with central pain that is a result of central 
sensitivity. 
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99. The method of claim 53 in which the step of assessing 
a Subject's brain function further includes the step of making 
brain measures to identify the presence of one or more brain 
activities associated with central pain that is a result of abnor 
mal network connectivity. 
k k k k k 
